🚀💰My plan to make $8k by Monday Morning?

[URGENT] ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from Millionaire Publishing If you dread Monday mornings, this might change that. Every Monday I open my trading account to potential profits as high as $8,780… $9,177… even $16,000. All thanks to a little known loophole called the weekend windfall. You'll never hear about it from the mainstream media... So if you want to change your weekends forever, Watch this brief 10 minute video now that explains everything -Tim Sykes Results are not typical. I teach methods that have made other traders money, but that does not guarantee you will make any money. Success in trading requires hard work and dedication. Past performance does not indicate future results. All trading carries risks. This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com Today's Bonus Content: Find Hidden Companies with Our Exclusive Free Report! By clicking this link, you are subscribing to receive emails from Krypton Street Newsletter.

>>>> Important Pre-IPO Opportunity <<<<

ELON MUSK TO ANNOUNCE "SUPER-IPO" ON MARCH 13, 2025? ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from Paradigm Press >>>> Important Pre-IPO Opportunity <<<<   Dear Reader,   The largest IPO in history is about to take place…   I'm talking about Elon Musk's $180 billion giant Starlink.   According to Quartz, "Elon Musk's Starlink IPO may lift off very soon."   And here's the kicker…   Most investors will only be able to get in AFTER Starlink goes public, when the biggest money has already been made.   Sadly, they'll all be leaving A LOT of money on the table!   But not you…   If you act fast, you could have the rare chance to profit BEFORE the IPO takes place.   Best of all, you can do it right inside your ordinary brokerage account… and all you need is as little as $50 and a few minutes of time.   Click here now for the time-sensitive details on this "backdoor" play.   Sincerely,   James Altucher   This ad is sent on behalf of Paradigm Press, LLC, at 1001 Cathedral St., Baltimore, MD 21201. If you're not interested in this opportunity from Paradigm Press, LLC, please click here to remove your email from these offers. This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com Today's Bonus Content: Get Instant Alerts on Companies that Could Explode in 2025! (By clicking this link, you are subscribing to receive messages from Stock News Trends)

Re: FINAL NOTICE: Your link expires tonight at 11:59 pm

🔥 Final Call – Lock in Your Weekly Winners Alert Now!...............................................................................................................................

Dear Reader,

Unsubscribe

Quick Reminder: Hurry, future Weekly Winners member! Our extended deadline for StockEarnings Weekly Winners Membership ends tonight at 11:59 PM.

You still have time to sign up and receive your first stock trade in your account instantly.

👉 Few Hours Left to Secure Your Quaterly Membership. Get in Here

--------------I sent you the email below on Tuesday (March, 11 2025)--------------

I talk with traders like you every day.

And through these talks, I've learned that most traders want three things from a trading service:

• A steady flow of low-risk trade suggestions with a good chance at big gains
  
  
• Easy-to-execute trades with short holding times
  
  
• A focus on stocks that don't cost a fortune to trade
  
  

I've got a service that provides all that (and much more).

🚀 Introducing Weekly Winners – Smarter Trading, Made Easier 🎯

Weekly Winners is the simplest trading service I know of – it does all the stock research for you (so you have more time to do what you really want).

The power behind this service is a proprietary algorithm I developed over 17 years ago.

That baby pores through tons of data on thousands of stocks to find low-risk trades with short holding times (making it perfect for conservative traders like you).

Best of all, these are stocks that cost $50 or less a share (enabling you to spread your money around on more trade opportunities).

All you do is wait for my simple trade instructions, which cover everything you need to know to execute the trade, including…

• Company name and ticker symbol
  
  
• Current stock price
  
  
• Limit order price
  
  
• Maximum point of entry
  
  
• Suggested stop loss
  
  
• Alerts on when to exit the trade and at what price
  
  
• Real-time trade commentary
  

As a Weekly Winners member, you'll get one or two trade recommendations every month (they're all basic stock trades, so there's no complicated options strategies to deal with).

My next recommendation is only two days away…

👉 On Thursday, March 13, I'll Release the Next Weekly Winners Trade

I'd like you to get this trade (I'm really excited about it – I think it has a great shot at being our biggest winner so far in 2025).

So, here's the deal – join Weekly Winners before Thursday, March 13, and I'll give you a Quarterly membership and your first stock trade.

That reflects a monster discount for Weekly Winners, and your payment is just a one-off – you'll NEVER have to pay another cent for the next quarter.

But remember, you have to be a Weekly Winners member before March 13 to get this

deal (and my next trade).

So don't dally… join Weekly Winners today and get regular low-risk stock recommendations!

Yours for better trading,

Best Regards,

Hiral Ghelani Founder & CEO Stock Earnings .com 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA Phone: 1-877-678-6257 (Mon to Fri | 9am to 5pm EST)

P.S. Weekly Winners works in up and down markets because it features both stock buys and short sells (so you can trade with confidence in all market conditions). And it's fully guaranteed for 90 days – you either love the service or you can get your money back for any reason. P.P.S. I almost forgot – join Weekly Winners right now and you'll also get three valuable bonuses: BONUS #1 – How to Trade Earnings Manual BONUS #2 – Timing is Everything Special Report BONUS #3 – The Right Way to Use Options in Earnings Season Video And rest easy – there's no risk to signing up for Weekly Winners. These must-have trading tools reveal strategies the pros use to consistently beat the markets. Use them and you'll trade with MUCH more confidence. So go ahead…

👉 Yes! I Want to Claim My Free Bonuses and My 1st Trade Alert in Weekly Winners 📈

---

Disclaimer & Important Information

StockEarnings.com is owned and published by StockEarnings, Inc ("SE"). Their results are not typical and your experience will vary based upon your effort, education, business model, and market forces beyond our control.

SE is not an investment adviser or a broker-dealer. SE is not a financial adviser and does not provide any individualized investment advice. You should perform your own independent research on potential investments and consult with your financial adviser to determine whether an investment is appropriate given your financial needs, objectives, and risk appetite. Readers are advised that this publication is issued solely for informational purposes and should not be construed as an offer to sell or the solicitation of an offer to buy any security.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

None of the case studies, examples, testimonials, or investment return or income claims on this site or through this service is a guarantee of any income or investment results for you. Trading in securities involves risks, including the risk of losing some or all of your investment. For additional SE disclosures and policies, please click here.

Unsubscribe

Breaking Now: Palisade Bio (Nasdaq: PALI) Just Hit Our Radar—Take a Look Before Tomorrow Morning

*Sponsored Market Crux Exclusive! This Came In Late, But There’s No Way It Could Wait Until  Tomorrow Morning! Take A Look At Palisade Bio (Nasdaq: PALI) Before  You Call It A Night… Here’s Why Palisade Bio (Nasdaq: PALI) is Topping Our  Watchlist Right Now. Analyst Coverage: Brookline Capital Markets has issued a $38 target, which suggests a 4,041% upside potential from today’s close. Limited Float: With fewer than 2.75M shares in its float, Palisade Bio (Nasdaq: PALI) could witness significant swings if demand begins to shift. Recent Recognition: Palisade Bio (Nasdaq: PALI) has shown short-term moves, including an approximate 139% move in under 24 hours. Expanding Market: The inflammatory bowel disease treatment market is projected to reach $22B in 2025 and surpass $31B by 2034. Upcoming Milestones: Palisade Bio (Nasdaq: PALI) is approaching key developments, including Phase 1 topline data expected in early 2025. Consider adding Palisade Bio (Nasdaq: PALI) to your radar before tomorrow’s bell rings. March 13, 2025 Dear Reader, Something came across my desk this afternoon, and let’s just say—this couldn’t wait until morning.  Friday, 3/14/2025 is shaping up to be an interesting one, and you’ll see why in just a second. When analysts start dropping targets that turn heads, you need to pay attention.  Right now, there’s a little-known company operating in a space projected to exceed $22B this year—yet it’s still flying under the radar… For now. Because if analysts are anywhere close to being right, that won’t be the case much longer. The name? Palisade Bio, Inc. (Nasdaq: PALI). And once you see the targets being set—including potential upsides of over 1,400% and 4,000% from today’s close—you’re going to want to keep this one on your radar first thing tomorrow.  Palisade Bio (Nasdaq: PALI) Gets $38 Target—Which Suggests Over 4,041% Upside Potential… Palisade Bio (Nasdaq: PALI) has a market cap of just around $2.7M, a sign that it appears to be flying under the radar—but recent analyst attention suggests that might not be the case for much longer. With less than 2.75M shares listed in its float, Palisade Bio (Nasdaq: PALI) is structured in a way that could see significant movement if demand begins to shift.  Analysts from two firms have recently initiated coverage, issuing targets that are difficult to ignore.  One of the oldest institutions on Wall Street, Ladenburg Thalmann,  has issued a $14 target on Palisade Bio (Nasdaq: PALI), which suggests a potential upside of 1,425%. Meanwhile, Benzigna reports that Brookline Capital Markets has set a $38 target, which suggests a potential upside of 4,041% from today’s $.9175 close. Palisade Bio (Nasdaq: PALI) has been trending near or above several key moving averages, showing signs that the potential for momentum may be building. 5-Day: 0.9163 20-Day: 0.9088 With its 50-Day moving average at 1.3034, 100-Day at 1.8871, and 200-Day at 2.9383, we will have all eyes on Palisade Bio (Nasdaq: PALI) tomorrow. (Friday, 3/14/2025) Just take a look at some of Palisade Bio, Inc. (Nasdaq: PALI)’s recent overnight and multi-day moves: +139% Approx. Move: 12/11/2024 → 12/12/2024 (From $1.38 to $3.30) +46% Approx. Move: 03/04/2025 → 03/12/2025 (From $0.75 to $1.10) +37% Approx. Move: 01/03/2025 → 01/06/2025 (From $1.78 to $2.44) Keep reading to see why Palisade Bio (Nasdaq: PALI) is topping our watchlist tomorrow morning. Palisade Bio (Nasdaq: PALI) Is Advancing Biopharma Research In An Expanding Market… Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on developing precision therapies for immune, inflammatory, and fibrotic diseases—areas where current treatment options often fall short. The company’s lead program, PALI-2108, is designed to target ulcerative colitis (UC), a chronic inflammatory condition affecting a large patient population worldwide.  With a gut-restricted mechanism of action, PALI-2108 aims to provide a more targeted approach with fewer systemic side effects compared to existing treatments. Palisade Bio (Nasdaq: PALI) isn’t stopping there.  The company is also advancing PALI-1908, an early-stage therapy designed for fibrostenotic Crohn’s disease, another severe gastrointestinal condition. With a growing market and an expanding pipeline of next-generation therapies, Palisade Bio (Nasdaq: PALI) is working to establish itself as a key player in the biotech space. A Booming Market: IBD Treatments Projected To Reach $31B By 2034 The demand for better treatments in this space isn’t just increasing—it’s accelerating at a pace that’s hard to ignore.  The global inflammatory bowel disease (IBD) treatment market is projected to push past $22B in 2025 and expand beyond $31B by 2034, reflecting the growing need for more advanced and effective solutions.  In the U.S. alone, spending is expected to approach $10B next year, driven by a combination of factors reshaping the healthcare landscape. A steady rise in ulcerative colitis and Crohn’s disease cases has placed a spotlight on the urgent need for improved therapies, as countless individuals continue to struggle with these chronic conditions.  At the same time, the demand for safer, more effective treatment options is driving innovation, with researchers and biotech companies racing to develop solutions that provide better outcomes with fewer side effects.  Breakthrough advancements in medical technology and precision medicine are also transforming the way these diseases are treated, allowing for more targeted approaches that could revolutionize patient care. With the market rapidly expanding and innovation pushing the boundaries of what’s possible, companies developing next-generation therapies are stepping into focus.  As the healthcare industry seeks to address these growing challenges, the spotlight is shifting toward those working on novel treatments—because the need for cutting-edge solutions has never been more urgent. Could Machine Learning And Targeted Therapies Could Give Palisade Bio (Nasdaq: PALI) An Edge? Palisade Bio (Nasdaq: PALI) isn’t following the conventional playbook when it comes to treatment development.  Rather than relying on broad, systemic approaches, the company is using precision medicine and machine learning to create targeted solutions designed to work where they’re needed most. Its lead candidate, PALI-2108, is a gut-restricted PDE4 inhibitor, specifically designed to focus on the affected area without unnecessary exposure to the rest of the body.  This approach aims to reduce side effects while enhancing effectiveness, addressing a critical need in the treatment of inflammatory conditions. Adding another layer of innovation, Palisade Bio (Nasdaq: PALI) is incorporating machine learning to refine patient selection.  By analyzing biomarkers, the company is working to identify those most likely to benefit from its therapies, increasing the chances of success.  With a strategy centered on precision and personalization, PALI-2108 is positioning itself as a potential breakthrough in the evolving IBD treatment market. Upcoming Milestones That Could Put Palisade Bio, Inc. (Nasdaq: PALI) in the Spotlight… Palisade Bio, Inc. (Nasdaq: PALI)’s clinical progress is accelerating, with key milestones expected over the next 12 months: Phase 1 trials for PALI-2108 → All five cohorts have been dosed, with topline data expected in the first half of 2025. Phase 1b/2a trials planned → The next step in clinical development, with potential regulatory advancements ahead. Pipeline expansion → Additional therapies targeting immune, inflammatory, and fibrotic diseases are in development. With multiple catalysts on the horizon, Palisade Bio (Nasdaq: PALI) has entered a phase where the potential for momentum could build quickly. Here’s 5 Reasons Why Palisade Bio (Nasdaq: PALI) is Topping Our Watchlist Tomorrow… 1. Upcoming Milestones: Palisade Bio (Nasdaq: PALI) is approaching key catalysts, including Phase 1 topline data expected in early 2025, Phase 1b/2a trials planned, and additional pipeline developments underway. 2. Analyst Coverage: Brookline Capital Markets has set a $38 target, which suggests an upside potential of 4,041%, while Ladenburg Thalmann has issued a $14 target, which suggests an upside potential of 1,425% for Palisade Bio, Inc. (Nasdaq: PALI). 3. Limited Float: With less than 2.75M shares in its float, Palisade Bio (Nasdaq: PALI) is structured in a way that could see significant movement if demand shifts. 4. Recent Market Recognition: Palisade Bio (Nasdaq: PALI) has shown multiple short-term moves, including an (approx.) 139% move in under 24 hours, a 46% (approx.) move in under 7 sessions and 37% (approx.) move from one session to the next.  5 Expanding Market: The inflammatory bowel disease treatment market, where Palisade Bio (Nasdaq: PALI) is developing next-generation therapies, is projected to reach $22B in 2025 and grow beyond $31B by 2034, with the U.S. market alone expected to approach $10B in 2025. Keep Palisade Bio (Nasdaq: PALI) On Your Radar Before Tomorrow Morning… Let’s be honest—biotech companies with low floats, recent analyst attention, and key developments on the horizon don’t stay in the shadows forever. With fewer than 2.75M shares in its float, multiple short-term moves exceeding 100%, and analysts setting targets that point to substantial upside potential, Palisade Bio (Nasdaq: PALI) is starting to look like one that won’t be flying under the radar much longer. We’ll be watching (PALI) closely heading into tomorrow morning.  It might be worth taking a look before you call it a night. Also, keep an eye out for my morning update. Have a good night. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/11/2025 and ending on 03/14/2025 to publicly disseminate information about (PALI:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC, or their members own shares of (PALI:US). Please see important disclosure information here: https://marketcrux.com/disclosure/pali/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice